RegenXBio Secures $250M Royalty Monetization Deal

RegenXBio ( (RGNX) ) has provided an update.

On May 16, 2025, REGENXBIO Inc. announced a strategic royalty monetization agreement with HealthCare Royalty Management, LLC, securing up to $250 million in non-dilutive funding through a limited recourse royalty bond. This agreement provides immediate capital of $150 million, extending the company’s cash runway into early 2027 and supporting its late-stage gene therapy programs. The deal allows REGENXBIO to leverage anticipated royalties from products like ZOLGENSMA® and potential future milestones, positioning the company to accelerate commercial preparations and maintain its leadership in gene therapy.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

Spark’s Take on RGNX Stock

According to Spark, TipRanks’ AI Analyst, RGNX is a Neutral.

RegenXBio’s overall score reflects a challenging financial position due to persistent losses and valuation concerns. However, strong clinical progress, strategic partnerships, and a robust cash position from recent earnings call data point to potential future growth. Technical indicators suggest cautious optimism, despite current volatility.

To see Spark’s full report on RGNX stock, click here.

More about RegenXBio

REGENXBIO Inc. is a biotechnology company focused on advancing gene therapy treatments for rare and retinal diseases. Founded in 2009, the company has developed a late-stage pipeline of one-time treatments, including RGX-202 for Duchenne, RGX-121 for MPS II, and RGX-111 for MPS I, among others. REGENXBIO collaborates with partners like Nippon Shinyaku and AbbVie and has treated thousands of patients with its AAV platform, including those receiving Novartis’ ZOLGENSMA®.

Average Trading Volume: 1,081,249

Technical Sentiment Signal: Sell

Current Market Cap: $445.9M

Find detailed analytics on RGNX stock on TipRanks’ Stock Analysis page.